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Allergol ImmunoRESEARCH LETTERAnaphylaxis to mefenamic acid in a patient
with new onset of systemic lupus
erythematosusTo the Editor:
Many studies have addressed the frequency of drug allergy
(DA) in systemic lupus erythematosus (SLE) patients. Some
studies suggest that there may be an increased risk in these
patients1–4 while others do not conﬁrm this.5–7 The conﬂicting
results may be due to differences in deﬁnition of drug allergy;
in the means of ascertaining allergic manifestations; and in the
choice of controls. SLE patients are more frequently exposed
to drugs, which, ‘‘per se’’, represent a risk factor for drug
allergy. Prompt recognition of DA, particularly anaphylaxis, is
crucial, as it may be life-threatening and the appropriate
treatment cannot be delayed. In a patient with SLE, the
differential diagnosis of drug allergy is challenging. Features
such as rash, fever and cytopenia may result from drug allergy
but may also be part of SLE manifestations. Furthermore,
drugs like sulphonamides are well known to exacerbate, or
even induce SLE.8,9
The authors report a case of a 32-year-old Caucasian
female housewife who presented at the emergency room
with rash, diffuse myalgias, dry mouth, paraesthesia and
dizziness. The symptoms started 90 minutes after taking a
250 mg tablet of mefenamic acid. She was thought to have
an allergic drug reaction and was treated with intramuscular
clemastin and IV methylprednisolone 250 mg. She was alert,
her blood pressure was 100/57 mmHg, her heart rate was
124 per minute and her temperature was normal. Despite
receiving clemastin and methylprednisolone, two hours later
she had a clinical deterioration starting with generalised
pruritus and worsening of generalised exanthema, myalgias
and arthralgias. She rapidly developed angio-oedema and
anaphylactic shock. Her temperature was 37.4 1C, her blood
pressure dropped to 73/45 mmHg and her heart rate was
120 per min. She was given dopamine, epinephrine and
250 mg of IV methylprednisolone and intravenous ﬂuids.
Blood cell count revealed a haemoglobin level of 7.9 g/dl
[11.5–16.5], a white blood cell count of 5.4 103/mL [4–11],
prothrombin time 22 s [13], d-dimers of 7.17 mg/L [0–0.6],
ﬁbrinogen of 2.6 g/L [2–5.0], SGPT 219 U/l [555]; SGOT
337 U/l [5–34]; SGGT 15 U/l [9–36], total bilirubin 0.8 mg/dlfront matter & 2009 SEICAP. Published by Elsevier Esp
r.2009.09.011
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pathol (Madr). 2010. doi:10.1016/j.aller.2009.09.011[0.2–1.2], LDH 628 U/l [125–243], albumin 2.8 g/dl [3.5–5],
CRP 6.31 mg/dl [0–0.8] and ESR 69 mm [0–2 5]. Chest x-ray
and ECG were normal. She was diagnosed with DA to
mefenamic acid and acute hepatic failure and was admitted
into the Intensive Care Unit.
In the Intensive Care Unit, life support care was
maintained and she started prednisolone 1 mg/Kg/day and
topical silver sulphadiazine for skin lesions. By the third day
she was haemodynamically stable, her liver function was
almost normal and the skin lesions were resolving.
This patient had a history of new onset of polyarthralgia
three weeks previous to this episode which was treated by
her general practitioner with mefenamic acid 250 mg
tablets bid. One week later, she had not improved and
cyclobenzaprine 10 mg qd was added to her treatment. She
stopped both drugs the following day because of malaise and
facial exanthema that resolved completely. She did not take
any other medications except for chronic treatment with
thyroxine for hypotiroidism. Laboratory tests done by her
general practitioner 11 days before this episode showed an
anti-nuclear antibody (ANA) of 1/2500 [o1/40] with
homogenous pattern, anti-dsDNA of 1/80 [o1/10], Rheu-
matoid Factor of 28 IU/ml [o14], negative Waaler-Rose
test, white blood cell count 3.96 103/mL [4–11 103/mL],
lymphocytes of 1.0 103/mL [1.5–3.5], CPR 3.94 [o6.0] and
ESR of 90 mm [o20].
Repeat testing at the hospital conﬁrmed ANA positivity,
anti-dsDNA of 40.0 IU/ml [o4.2], anti-histone 200 U/ml
[o40], positive anti-SSA and anti-SSB, negative anticardio-
lipin and anti-beta2GPI antibodies, low complement levels
with C3 0.78 g/L [0.9–1.8] and C4 0.15 g/L [0.1–0.4],
haptoglobin 3.14 g/L [0,3–2], positive Coombs test, free
T3 was 71 pg/% [230–530], free T4 1.2 ng/% [0.78–1.94] and
TSH 6.5 mU/ml [0.4–4]. As her d-dimer was above normal
level, a peripheral limbs Doppler test was done but it
showed no vascular occlusions.
Lymphoblastic proliferation test to mefenamic acid was
negative. Drug challenge test was not performed as it might
be hazardous in this patient.
SLE was diagnosed on the basis of a positive ANA and anti-
dsDNA, Coombs positive haemolytic anaemia, leucopenia,
lymphopenia, arthritis and low C3 and C4 levels. Prednisone
was tapered to 20 mg by the time of hospital discharge and
added hydroxychloroquine 200 mg qd. Her clinical and
laboratory (Figure 1) evolution were favourable and she
was discharged on the 21st hospital day in a healthy
condition.an˜a, S.L. All rights reserved.
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Figure 1 Evolution of Hgb, SGOT and SGPT over time. Hgb-haemoglobin, SGOT-Serum glutamic oxaloacetic transaminase,
SGPT-Serum glutamic pyruvic transaminase.
RESEARCH LETTER2She continues to be followed up as an outpatient for her
SLE. One year after this episode, the ANA, anti-dsDNA, anti-
SSA, anti-SSB and anti-histone autoantibodies remain posi-
tive at nearly identical levels.
Although pharmacological inhibition of cyclooxygenase
with overproduction of cysteinyl leukotrienes is one of the
most important mechanisms of the adverse mechanism of
NSAIDs, in this patient the occurrence of a rapid onset of
rash, generalised pruritus, angio-oedema and hypotension
suggest an allergic-type response, presumably by immuno-
logical IgE-mediated mechanism.10 Previous contact with
the culprit drug, corresponding to the sensitisation period,
supports the diagnosis of DA.11 Skin testing to NSAIDs, prick
and intradermal testing, are usually negative and correlate
poorly with the clinical history of hypersensitivity reactions.
Moreover, in vitro tests are not useful in establishing
diagnosis.10 Controlled oral challenge test remains the gold
standard but it was not performed because of its high risk of
inducing a life threatening reaction.
In this case, a two-step reaction with rash and dizziness
occurring 90 min after the ingestion of mefenamic acid and
then the worsening of exanthema, pruritus, angio-oedema
and hypotension two hours after the ﬁrst clinical manifesta-
tions that were treated with parental steroids and anti-
histamines, support mefenamic acid as the most likely cause
for anaphylaxis. Anaphylaxis usually begins within 5 to
30 min after antigen exposure, but a delay of one hour or
more can occur.11 Anaphylactic shock can be biphasic and,
several hours after its initial presentation, a new episode
may begin and it is not unusual for the second episode to be
more severe.11 Causality assessment was done applying the
Hutchinson et al. algorithm for Adverse Drug Reaction, and
corroborates the association between the drug and DA
(score 5=probable).12
Concerning laboratory results, the raise in hepatic
enzymes, thrombocytopenia, lymphopenia and haemolytic
anaemia may be due to drug toxicity or to concomitant
complement and ﬁbrinolytic cascade activation and immune
complex activation. Renal and hepatic manifestations may
also occur as a part of a generalised allergic reaction.11 Also,
both anaphylaxis and mefenamic acid can lower C3 and C4
levels. The presence of haemolytic anaemia, lymphopenia,
low C3 and C4 are features of SLE, but could not be
deﬁnitively attributed in this context.Please cite this article as: Couto M, et al. Anaphylaxis to mefenamic
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(DIL). This has been reported for more than 80 drugs. The
strongest evidence of causality is for procainamide, hydra-
lazine and isoniazid.8,13 Drugs such as anti-hypertensives,
antibiotics and anti-convulsivants are of low risk.8 Among
NSAID only celecoxib14 has been implicated in DIL and there
are no published case reports for mefenamic acid. The
typical features of systemic DIL are mild SLE manifestations
with positive ANA and anti-histone antibodies temporally
related to drug exposure which typically resolves after
discontinuation of the offending drug.8,13 Despite the
presence of anti-histones our patient had polyarthritis,
anti-dsDNA and hypocomplementemia which play against
the possibility of DIL. In addition, more than a year after the
withdrawal of mefenamic acid the patient maintained these
clinical and laboratory features.
However, drugs such as sulphonamides,9 tetracyclines,15
griseofulvin,16 piroxicam,17 ibuprofen18 and oestrogens19
have been reported to exacerbate SLE or to trigger new
cases. Before this report, mefenamic acid has not been
reported in any of the cases.
In this case, the most likely explanation is that anaphy-
laxis occurred in a patient with recent SLE. Whether
mefenamic acid was implicated in exacerbation of the
disease is difﬁcult to discount or prove.
This case illustrates the difﬁculties and the wide
differential diagnosis in an SLE patient who presents with
a drug reaction. The attribution of the presenting symptoms
to DA, DIL, drug triggering of SLE onset / exacerbation or to
the underlying SLE and/or to the drugs used to treat SLE its
coexisting conditions is a major challenge. We discuss some
clues to approach this problem in the clinical setting.
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